NFKB1 and irritable bowel syndrome: MiR‐223 is involved in the development of IBD, including NF‐κB signaling, the IL23/Th17 pathway and the NLRP3–IL‐1β circuit, and could be a biomarker and therapeutic target.22, 23, 24